People with congenital colorblindness can see about 1 percent of the colors that a typical person can, and the condition can have negative impacts on their lives. Colorblindness can prevent people from becoming pilots or electricians, as well as limit their vision at night, putting themselves and others in danger.
Now a pair of researchers are teaming up with the startup Avalanche Biotechnologies to develop a genetic therapy that could cure colorblindness. Colorblindness, which affects 32 million Americans, is the result of a genetic mutation on the X chromosome.
Since men only have one X chromosome, they are more likely to be colorblind than women, who can often overcome a possible mutation with their second X chromosome. Since genes hold the key to colorblindness, vision researchers Jay and Maureen Neitz believe that gene therapy could hold the cure.